Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients

Jürgen Floege(Westfälische Hochschule), Stuart M. Sprague(NorthShore University HealthSystem), Johannes F.E. Mann(Katholische Stiftungshochschule München), Adrian Covic(Grigore T. Popa University of Medicine and Pharmacy), Markus Ketteler(Robert Bosch Hospital), Laura Lisk(Vifor Pharma (Switzerland)), Anjay Rastogi(University of California, Los Angeles), Edward Chong(Vifor Pharma (Switzerland)), Bruce Spinowitz, Sylvain Gaillard(Vifor Pharma (Switzerland))
Nephrology Dialysis Transplantation
February 16, 2015
10.1093/ndt/gfv006
Cited by 142

Related Papers

Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
|New England Journal of Medicine|2024|1.5k
Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters
|Kidney International|2017|998
Urinary Sodium and Potassium Excretion and Risk of Cardiovascular Events
|JAMA|2011|566
Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
|Kidney International|2016|474